	US 12,319,744 B2
	Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein C receptor (EPCR)
Vijaya M. Lella, Tyler, TX (US); Usha R. Pendurthi, Tyler, TX (US); and Jhansi L. Magisetty, Tyler, TX (US)
Assigned to Board of Regents, The University of Texas System, Austin, TX (US)
Appl. No. 17/273,965
Filed by BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US)
PCT Filed Sep. 5, 2019, PCT No. PCT/US2019/049656 § 371(c)(1), (2) Date Mar. 5, 2021, PCT Pub. No. WO2020/051277, PCT Pub. Date Mar. 12, 2020.
Claims priority of provisional application 62/727,613, filed on Sep. 6, 2018.
Prior Publication US 2021/0355231 A1, Nov. 18, 2021
Int. Cl. A61P 19/02 (2006.01); A61K 38/48 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2896 (2013.01) [A61K 38/4846 (2013.01); A61P 19/02 (2018.01); A61K 2039/54 (2013.01)]

19 Claims

1. A method of treating a mammalian subject having hemophilic arthropathy comprising administering to said subject an effective amount of an antibody specific for Endothelial Protein C Receptor (EPCR), wherein the antibody is administered subcutaneously, and wherein the antibody is administered at a dose of 0.1 to 1 mg/kg/body weight.